相关实验视频

Updated: Jun 28, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

针对急性髓性白血病治疗的目标PRAME

Jinjun Yang¹, Mengran Chen¹, Jing Ye²

¹Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.

Frontiers in immunology

|April 10, 2024

概括

在黑色素瘤中优先表达抗原 (PRAME) 是急性髓性白血病 (AML) 的治疗点,特别是在预后不佳的患者中. 针对PRAME的免疫疗法为治疗AML提供了一个新的途径.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

急性髓性白血病 (AML) 结果对于特定患者群体来说仍然很差,包括老年人和具有不良风险因素的人.
T细胞免疫疗法在各种癌症中取得了成功,但在AML中面临挑战,原因是骨髓细胞爆发上缺乏独特的表面抗原.
在黑色素瘤中优先表达的抗原 (PRAME),癌症丸抗原,在AML中异常表达,在正常的造血细胞中不存在,使其成为潜在的治疗点.

研究的目的:

审查PRAME在AML中的结构,功能和影响.
探索PRAME作为AML抗原特异性免疫治疗的标的潜力.

主要方法:

关于PRAME在AML中的作用的文献综述.
在正常的造血细胞和AML爆发中分析PRAME表达.
评估PRAME的预后意义和治疗潜力.

主要成果:

在AML中,PRAME的表达异常,在正常的造血细胞中不存在.
有证据表明,PRAME是AML治疗的可行目标.
在AML患者中,PRAME表达与预后和随访相关.

结论:

在AML中,PRAME是新型免疫疗法的一个有希望的目标.
针对PRAME的抗原特异性免疫疗法可以改善AML患者的治疗结果,特别是那些预后不佳的患者.

关键词:

普拉梅姆是什么意思?急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.收养的T细胞疗法免疫疗法免疫疗法与白血病相关的抗原.最少残留疾病的最小残留疾病.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...